Variation in the glucose transporter gene SLC2A2 is associated with glycaemic response to metformin

Metformin is the first-line antidiabetic drug with over 100 million users worldwide, yet its mechanism of action remains unclear1. Here the Metformin Genetics (MetGen) Consortium reports a three-stage genome-wide association study (GWAS), consisting of 13,123 participants of different ancestries. Th...

Full description

Bibliographic Details
Main Authors:	Kaixin, Z, Yee, S, Seiser, E, van Leeuwen, N, Tavendale, R, Bennett, A, Groves, C, Coleman, R, van der Heijden, A, Beulens, J, de Keyser, C, Zaharenko, L, Rotroff, D, Out, M, Jablonski, K, Chen, L, Javorský, M, Židzik, J, Levin, A, William, L, Dujic, T, Semiz, S, Kubo, M, Chien, H, Maeda, S, Witte, J, Wu, L, Tkáč, I, Kooy, A, van Schaik, R, Stehouwer, C, Logie, L, MetGen Investigators, DPP Investigators, ACCORD Investigators, Sutherland, C, Klovins, J, Pirags, V, Hofman, A, Stricker, B, Motsinger-Reif, A, Wagner, M, Innocenti, F, 't Hart, L, Holman, R, McCarthy, M, Hedderson, M, Palmer, C, Florez, J, Giacomini, K, Pearson, E
Format:	Journal article
Published:	Nature Publishing Group 2016

Variation in the glucose transporter gene SLC2A2 is associated with glycaemic response to metformin

Similar Items